VTX-1 Liquid Biopsy System
Cancer Research & Monitoring
Key Facts
About Vortex Biosciences
Vortex Biosciences is a private, commercial-stage diagnostics company pioneering a unique microfluidic platform for the label-free, gentle capture of viable circulating tumor cells (CTCs). Founded in 2012 and headquartered in Cambridge, UK, with a new laboratory in Manchester, the company is positioned at the forefront of the liquid biopsy market, enabling multi-omics analysis of CTCs for research and clinical applications. Key milestones include the launch of its VTX-1 system, a clinical study to advance cancer monitoring, and a strategic partnership with AstraZeneca through an exchange program. The company is leveraging its technology to support precision oncology by providing a real-time, functional view of cancer progression and treatment resistance.
View full company profile